UNSPSC 51313418: Brompheniramine maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IXA7C9ZN03, chemically known as 3-(p-bromophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but more generally known as brompheniramine maleate, which bears US NIH Compound Identifier 6834. European Medicines Agency schedules Brompheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00881MIG.

UNSPSC 51313418 Brompheniramine maleate is a Commodity code under which state and local governments procure pharmaceutical products, though the recent activity under this specific code entry does not reflect brompheniramine maleate procurement directly. Instead, the opportunities tagged to this code show state and local health agencies, county governments, and cooperative purchasing alliances buying a broader range of pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and OTC medications through competitive bidding and RFP processes. The issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). Work solicited under the code spans annual pharmaceutical supply agreements with quarterly or ongoing delivery schedules to health facilities, direct-to-manufacturer prescription programs, and standing contracts for generic and OTC product distribution through authorized wholesalers.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon based on recent solicitations. Representative opportunities include Seminole County's IFB60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026. Contracts typically carry two-year initial terms with optional renewals, require compliance with cGMP and Drug Supply Chain Security Act standards, and demand substantial insurance coverage and E-Verify certification.